Saturday, June 22, 2024

Collaboration Enhanced as Merck Signs MoU with KAIST to Advance Scientific Research

Similar articles

Collaboration between Merck and KAIST which Merck is a leading science and technology company, has entered into a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Technology (KAIST).

This collaboration aims to enhance the research and development ecosystem in South Korea, focusing on industrial applications. The partnership represents a significant step towards advancing biotechnology in both local and global life science industries.

“We are delighted that Merck and KAIST, which share an innovation mindset and a vision for scientific advancement, will work closely together,” said Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science. “Advancing research and preparing the next generation of scientists is key to discovering new medicines to meet the needs of a global population – this is how we impact life and health with science.”

Merck will support KAIST by providing products from its chemistry and biology portfolios for laboratory research. Additionally, the company will offer development opportunities for KAIST researchers, including participation in annual international programs such as the Innovation Cup and the Curious Future Insight Conference. Fellowships for graduate students and awards for professors will also be part of the collaboration. A new experience lab will be established in Korea to help researchers improve their skills in developing application notes and scientific workflows in areas like material analysis, drug discovery, and omics solutions.

The partnership will further include a research collaboration focusing on advancing innovation in prioritized research areas. Merck’s corporate venture fund, M Ventures, will team up with the KAIST entrepreneurial team to build a startup ecosystem as part of the collaboration.


Collaboration Between Merck and KAIST to Strengthen Global Scientific Community and Life Science Innovation

Kwang-Hyung Lee, President of KAIST, expressed enthusiasm about the partnership, stating, “We are delighted that Merck and KAIST, which share an innovation mindset and a vision for scientific advancement, will work closely together. We look forward to this partnership as an opportunity to strengthen the connection between Merck’s life science business and the global scientific community.”

Merck has had a presence in Korea for 30 years and has made several strategic investments to serve the region’s biopharmaceutical industry. In March, the company announced a €300 million investment to build a new bioprocessing production facility in Daejeon.

About Merck: Merck is a leading science and technology company that operates across life sciences, healthcare, and electronics. With approximately 63,000 employees, Merck aims to make a positive difference in millions of people’s lives every day. The company provides products and services that accelerate drug development and manufacturing, discovers unique ways to treat challenging diseases, and enables the intelligence of devices. In 2023, Merck generated sales of €21 billion in 65 countries.

You can follow our news on our Telegram and LinkedIn accounts.

Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand, except in the United States and Canada, where its business sectors operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

This collaboration with KAIST exemplifies Merck’s commitment to advancing scientific research and development through strategic partnerships, reflecting its ongoing dedication to innovation and progress in the life sciences industry.

Resource: Businesswire, May 29, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article